With the EU MDR deadline postponed, MedTech Summit looks at what it means for the medtech industry.
On Friday the 3rd of April 2020, the EU Commission released the highly anticipated statement regarding the postponement of the EU Medical Device Regulation (MDR) date of application. Just two weeks later, on 17th of April, European Parliament voted on this with 693 in favour, with just 1 vote against it (and 2 abstained), advancing this proposal to the European Council for final sign-off. So long as this is law before the original MDR date of application, the new deadline will be the 26th May 2021 offering Medical Device, Software and Combination Product manufacturers one more year to ensure their processes and products meet the increasingly stringent regulatory requirements.
The widespread and ongoing need for ventilators, assistive devices, technology and vaccines were a primary reason for the extension of the EU MDR. As Vice-President for Promoting our European Way of Life, Margaritis Schinas, says:
The recognition of the necessity to accelerate certain products to market highlights a key challenge of the increasingly stringent regulations which, at this moment in time, would increase timelines from concept to market and delay patients from receiving potentially life-changing treatments.
Regulators in some countries have already relaxed regulations in order to get devices onto the market quickly in the effort to reduce the devastation of COVID-19, and the delay of the EU MDR will bring further relief.
Under the increasing social and organisational pressures brought about by this global pandemic, and with many teams dispersed as some tackle the corona virus on the front-line and others do their part remotely, the industry consensus it that this postponement was absolutely necessary in light of these current circumstances.
Beyond freeing up resources to help combat COVID-19, what is hoped is that this additional year will increase awareness and provide the opportunity for manufacturers producing patient-crucial (but not necessarily profitable) devices to recognise the patient value of their product, and that some sort of regulatory oversight will be developed across Europe to ensure minimal product fallout across the sector.
In the MedTech 2020: EU MDR & IVDR Compliance Survey only 22% of companies indicated that they would be extending their MDD certificate for all of their products, which, with only a small number of EU MDR certified products on the market at present, indicates that a significantly large proportion of products may be dropped due to the new regulations.
Originally the EU Commission brought in the new medical device regulations "to ensure better protection of public health and patient safety". Ultimately this was deemed necessary to protect end users following some major adverse events that highlighted flaws in the previous regulations. However, the extension of the EU MDR is just as crucial to public health and patient safety as it is to manufacturers, as it:
At a time of unprecedented change and just weeks before the original deadline was set to kick-in, this postponement could not have come at a more crucial time.
Our EU MDR & IVDR Compliance survey carried out earlier this year showed that only 17% of respondents felt their company was 'fully prepared' for EU MDR implementation, with reasons given for the lack of readiness including; a necessity for more guidance documents; Notified Body uncertainty; and timelines. See the full report here.
This showcases that for many companies in the industry working tirelessly under the weight of this looming regulatory deadline, alongside challenges like BREXIT and COVID-19, the deadline postponement could not have come at a more pivotal time.